Business
Acquisition of global vaccine adjuvant specialist
Acquisition of global vaccine adjuvant specialist.
About this update from Croda International Plc
[{"type":"text","content":"\n \nRNS Number : 6004K Croda International PLC 17 December 2018 \n\n17 December 2018 \n \nCroda International Plc\n \nAcquisition of global vaccine adjuvant specialist\n \nCroda International Plc ('Croda') today announces that a definitive agreement has been signed with Brenntag Nordic A/S to acquire Brenntag Biosector A/S ('Biosector'). Biosector is a specialist in the manufacture and supply of adjuvants serving the human and veterinary vaccine market. The total consideration is €72 million in cash and the transaction is expected to close by the end of 2018. \n \nBiosector was founded in 1939 and operates from a GMP-certified adjuvants manufacturing facility in Frederikssund, Denmark. Its product portfolio comprises innovative aluminium and saponin-based adjuvants. Aluminium-based adjuvants are extensively used in human and veterinary vaccines to increase their effectiveness. They also provide a platform to introduce new technically advanced saponin-based adjuvants. \n \nVaccine adjuvants are a natural extension to Croda's market leading, high-purity excipient delivery systems in its Health Care business. These adjuvants represent a niche, high-growth market, driven by increased healthcare spending alongside advances in biotechnology and the growing need for preventative treatments. Biosector is differentiated through its high quality portfolio of adjuvants, with a strong position in human applications.\n \nOn completion, Biosector will be integrated into Croda's Health Care business within the Life Sciences sector. It will continue to be led by its dedicated team, all of whom have extensive, class leading credentials and pharmaceutical experience. Croda will leverage its formulation and purification expertise to accelerate the development of Biosector's rich pipeline of next generation adjuvant systems. Croda will also utilise its dedicated global sales network to deliver Biosector's g...